60 Degrees Pharmaceuticals (SXTP) Retained Earnings (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Retained Earnings of -$50.0 million for Q1 2026, down 39905.31% year-over-year from N/an in Q1 2025, and down 35151.21% quarter-over-quarter from $142598.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Retained Earnings (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Retained Earnings for 5 consecutive years, with -$50.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 39905.31% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$50.0 million (down 39905.31% YoY), while the FY2025 annual figure was $142598.0, down 99.59% from the prior year.
- Retained Earnings retreated to -$50.0 million in Q1 2026 per SXTP's latest filing, from $142598.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $41.2 million in Q3 2025 and bottomed at -$50.0 million in Q1 2026.
- Historically, Retained Earnings has averaged $6.8 million across 5 years, with a median of $142598.0 in 2025.
- On a YoY basis, Retained Earnings climbed as much as 40660.6% in 2024 and fell as far as 47384.45% in 2024.
- 60 Degrees Pharmaceuticals' Retained Earnings stood at $5.2 million in 2022, then sank by 97.38% to $135561.0 in 2023, then soared by 25615.83% to $34.9 million in 2024, then slumped by 99.59% to $142598.0 in 2025, then tumbled by 35151.21% to -$50.0 million in 2026.
- Business Quant data shows SXTP's Retained Earnings at -$50.0 million in Q1 2026, $142598.0 in Q4 2025, and $41.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 4.38 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -52.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.98 Mn |
| Dec 31, 2025 | 142,598.00 |
| Sep 30, 2025 | 41.17 Mn |
| Jun 30, 2025 | 36.86 Mn |
| Mar 31, 2025 | 125,567.00 |
| Dec 31, 2024 | 34.86 Mn |
| Sep 30, 2024 | -38.48 Mn |
| Jun 30, 2024 | 29.37 Mn |
| Mar 31, 2024 | 29.36 Mn |
| Dec 31, 2023 | 135,561.00 |
| Sep 30, 2023 | 81,386.00 |
| Jun 30, 2023 | 72,044.00 |
| Dec 31, 2022 | 5.16 Mn |